To evaluate the regulatory phenotype of t(6;9) as compared to FLT3-ITD or NPM1 AML, we ranked the DNaseI data by the fold-change of the DHS tag count between NPM1 and FLT3-ITD patients, and plotted the t(6;9) DNaseI signal alongside (Fig. 1C, left). This evidence concerns the gene NPM1 and acute myeloid leukemia.